|
Combining tradition with modernity: Bayer hones its brand profile
|
04 April 2018 |
|
Bayer announces publication of larotrectinib data in The New England Journal of Medicine
|
26 February 2018 |
|
FDA report reaffirms safety profile and effectiveness of Bayer's Xarelto® in routine clinical practice
|
16 January 2018 |
|
Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer
|
17 November 2017 |
|
New scholarships worth EUR 417,000 awarded by Bayer Foundation to promote international talents
|
21 September 2017 |
|
Bayer's Rivaroxaban demonstrated superior protection against recurrent venous thromboembolism compared with Aspirin in EINSTEIN CHOICE study
|
23 March 2017 |
|
Another record year for Bayer - good progress with the acquisition of Monsanto
|
22 February 2017 |
|
Phase III COMPASS study with Bayer's rivaroxaban (Xarelto®) shows overwhelming efficacy and meets primary endpoint early
|
14 February 2017 |
|
Regorafenib granted priority review in the U.S. for second-line treatment of liver cancer
|
07 February 2017 |
|
Regorafenib from Bayer submitted to health authorities seeking approval in second-line treatment of liver cancer
|
09 November 2016 |
|
Bayer shows strong performance
|
26 October 2016 |
|
Bayer and CRISPR Therapeutics joint venture, named Casebia Therapeutics, establishes operations in Cambridge, MA
|
19 August 2016 |
|
Bayer Science & Education Foundation launches new round of funding
|
08 June 2016 |
|
Grants4Apps Accelerator 2016: You imagine, Bayer supports
|
10 May 2016 |
|
Bayer off to a successful start in 2016
|
26 April 2016 |
|
2016 Otto Bayer Award goes to Professor Dr. Dirk Trauner
|
25 April 2016 |
|
Bayer continues to grow its open innovation activities
|
09 February 2016 |
|
Bayer halves the price of its contraceptive implant Jadelle® for women in developing countries
|
08 January 2016 |
|
Bayer and CRISPR Therapeutics AG join forces to discover, develop and commercialize potential cures for serious genetic diseases
|
21 December 2015 |
|
Bayer's new five-year-contraceptive submitted for EU and US marketing authorization
|
20 November 2015 |